Cue Biopharma, Inc. (CUE)
| Previous close | 2.0800 |
| Open | 2.0900 |
| Bid | 2.1600 x 300 |
| Ask | 2.2000 x 100 |
| Day's range | 2.0750 - 2.2000 |
| 52-week range | 1.3030 - 5.1200 |
| Volume | |
| Avg. volume | 293,609 |
| Market cap | 106.042M |
| Beta (5Y monthly) | 2.01 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Cue Biopharma to Participate in Fireside Chat at The Citizens JMP Life Sciences Conference
BOSTON, May 07, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells, announced today that it will take part in a fireside chat at The Citizens JMP Life Sciences Conference being held in New York, May 13-14, 2024. During the fireside chat, Cue Biopharma will discuss current oncology and autoimmune disease strategies and progress. Presentation Detail
- GlobeNewswire
Cue Biopharma to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
BOSTON, April 24, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells, announced today that it will present an oral abstract and poster at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 31 – June 4, 2024 in Chicago, IL. The presentations will highlight the Company’s Phase 1 trials of its lead interleukin 2 (IL-2)-
- GlobeNewswire
Cue Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Updated Business Highlights
BOSTON, April 08, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells, today reported fourth quarter and full year 2023 financial results. Presented additional positive data from the ongoing Phase 1 trials of CUE-101 in first line (1L) human papillomavirus positive (HPV+) recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) in com
